Blog

Moving Toward More Targeted Treatments in Specialty Care

Intrinsiq Admin 11/16/2017 12:29:26 PM

The care of cancer patients has changed dramatically over the past decade – personalized medicine is no longer just an idea being discussed. With immunotherapy and treatments targeted at specific gene markers, Life Sciences companies are moving rapidly to try to introduce new therapies to the market.

Yet with the increased number of clinical trials, how do the sponsors find an adequate number of patients in those subpopulations?

When is Longitudinal Data Important to Life Sciences Companies?

Intrinsiq Admin 11/6/2017 12:41:30 PM

Life Sciences companies understand that longitudinal data will supply their brand teams with data to support their business decisions for a successful commercialization. The time-dimensioned and sequential relationships of longitudinal patient care intelligence reveal powerful insights into the drug therapy use and unmet needs of specifically-targeted patients - insights that lead to success. 

Practical Insights for Cell and Gene Therapy Commercialization

Intrinsiq Admin 8/9/2017 11:58:07 AM

Cell and gene therapies offer tremendous clinical promise along with immense commercial complexity. Innovators must overcome unprecedented challenges to develop highly customized solutions ... often reinventing approaches to commercialization planning. But where do they start? What pitfalls do they need to sidestep? What best practices exist in this developing market?


Understanding Data's Value to Specialty Products

Intrinsiq Admin 6/21/2017 12:13:18 PM

With the focus on value-based reimbursements, especially for specialty products, life sciences companies need to rely heavily on real-world data to show health outcomes and demonstrate the value of their brands. That kind of data will not come solely from claims or sales. And with patients under specialty care, the final outcomes may not be positive, making the effectiveness of treatment more important.

Five Oncology Trends Impacting the Patient Experience

5/1/2017 2:08:33 PM

In this five-chapter series Oncology Trends Impacting the Patient Experience, experts from AmerisourceBergen explore new challenges to product access, optimized clinical outcomes and commercial success and offer strategic recommendations for how pharmaceutical manufacturers can support prescribers and patients through the continuum of cancer care.

What Does Interoperability Mean to Patient Health?

Global Administrator 3/20/2017 5:47:36 PM

Despite years of discussion and initiatives designed to improve interoperability in healthcare, not much progress has been seen.  A set of industry standards for data elements would be almost impossible to implement, as it would require healthcare providers, payers, agencies and vendors to change current systems, reconstructing data models at a cost of millions, if not billions, of dollars.

HHS Institutes Ruling for More Transparency in Clinical Trials

Global Administrator 11/7/2016 5:46:44 PM

Recently the Department of Health and Human Service (HHS) issued a final rule specifying more expansive rules and stiffer penalties for those who conduct clinical trials, requiring the registration of certain clinical trials and submitting summary results information to ClinicalTrials.gov.  The ruling will apply to FDA-regulated drugs, biologicals and devices, and will become effective on January 1, 2017.

The Changing Business Model

Global Administrator 10/11/2016 1:42:05 PM

Life Science business models have changed.  Sales and marketing teams used to have to demonstrate the effectiveness and efficacy of a drug with clinical trial data and target physicians and practices to deliver those messages while dropping off sales samples. Pew Charitable Trust noted in one report that the pharmaceutical industry spent more than $24 billion on marketing to physicians in 2012.

Medication Adherence – What Data is Available to Provide Insight into Non-Compliance?

Global Administrator 10/11/2016 12:22:17 PM

When medications are not taken or refilled, pharmaceutical manufacturers are losing out on millions in revenue. But having poor compliance affects more than the drug companies. Patients are at risk to end up sicker or complicating their disease treatment, driving up hospitalizations or more extensive treatments.  Poor adherence to medication leads to increased morbidity and death and is estimated to incur costs of approximately $100 billion per year.

Pharmaceutical Companies Need Data to Improve Product Access and Utilization

Global Administrator 10/5/2016 1:44:54 PM

We are in a data-driven world.  Retail organizations use data and algorithms from social media sites in order to create targeted messages based on your browsing history.  Healthcare is no different.